Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vical Incorporated - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Vical Incorporated - Product Pipeline Review - 2015', provides an overview of the Vical Incorporated's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vical Incorporated including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Vical Incorporated's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vical Incorporated's pipeline products Reasons to buy - Evaluate Vical Incorporated's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vical Incorporated in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vical Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vical Incorporated and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vical Incorporated - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Vical Incorporated Snapshot 5 Vical Incorporated Overview 5 Key Information 5 Key Facts 5 Vical Incorporated - Research and Development Overview 6 Key Therapeutic Areas 6 Vical Incorporated - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Vical Incorporated - Pipeline Products Glance 14 Vical Incorporated - Clinical Stage Pipeline Products 14 Phase I Products/Combination Treatment Modalities 14 Vical Incorporated - Early Stage Pipeline Products 15 IND/CTA Filed Products/Combination Treatment Modalities 15 Preclinical Products/Combination Treatment Modalities 16 Vical Incorporated - Drug Profiles 17 VCLHB-01 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 VCLHM-01 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 CyMVectin 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ASP-2397 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 measles (bivalent) vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vical Incorporated - Pipeline Analysis 22 Vical Incorporated - Pipeline Products by Target 22 Vical Incorporated - Pipeline Products by Route of Administration 23 Vical Incorporated - Pipeline Products by Molecule Type 24 Vical Incorporated - Recent Pipeline Updates 25 Vical Incorporated - Dormant Projects 28 Vical Incorporated - Discontinued Pipeline Products 29 Discontinued Pipeline Product Profiles 29 HIV Vaccine 29 Vical Incorporated - Company Statement 30 Vical Incorporated - Locations And Subsidiaries 32 Head Office 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 33 Disclaimer 34
List of Tables
Vical Incorporated, Key Information 5 Vical Incorporated, Key Facts 5 Vical Incorporated - Pipeline by Indication, 2015 7 Vical Incorporated - Pipeline by Stage of Development, 2015 8 Vical Incorporated - Monotherapy Products in Pipeline, 2015 9 Vical Incorporated - Partnered Products in Pipeline, 2015 10 Vical Incorporated - Partnered Products/ Combination Treatment Modalities, 2015 11 Vical Incorporated - Out-Licensed Products in Pipeline, 2015 12 Vical Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2015 13 Vical Incorporated - Phase I, 2015 14 Vical Incorporated - IND/CTA Filed, 2015 15 Vical Incorporated - Preclinical, 2015 16 Vical Incorporated - Pipeline by Target, 2015 22 Vical Incorporated - Pipeline by Route of Administration, 2015 23 Vical Incorporated - Pipeline by Molecule Type, 2015 24 Vical Incorporated - Recent Pipeline Updates, 2015 25 Vical Incorporated - Dormant Developmental Projects,2015 28 Vical Incorporated - Discontinued Pipeline Products, 2015 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.